Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
Critical Reviews™ in Oncogenesis
SJR: 0.946 SNIP: 0.503 CiteScore™: 2

ISSN Druckformat: 0893-9675
ISSN Online: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.v17.i1.70
pages 97-121

Aberrant B-Raf Signaling in Human Cancer − 10 Years from Bench to Bedside

Michael Roring
Spemann Graduate School of Biology and Medicine, Centre for Biological Systems Analysis (ZBSA), Faculty for Biology, Albert-Ludwigs-University of Freiburg, Germany
Tilman Brummer
Centre for Biological Systems Analysis (ZBSA), Faculty for Biology, and Centre for Biological Signalling Studies BIOSS, Albert-Ludwigs-University of Freiburg, Germany

ABSTRAKT

The Ras/Raf/MEK/ERK signaling pathway plays a key role in physiological processes and is often dysregulated in cancer as well as developmental disorders such as the neuro-cardio-facio-cutaneous syndromes. Raf proteins, and in particular B-Raf, represent an important regulatory node, which is reflected by the fact that B-Raf represents the most frequently mutated protein kinase gene in human tumors. Many genetic aberrations of the BRAF proto-oncogene, such as different point mutations and chromosomal rearrangements, have been reported since 2002. As B-Raf displays aberrant activity in tumor entities for which no or only limited effective therapies are available, e.g., melanoma, ovarian, and colorectal carcinoma, a lot of hope and effort has been placed on strategies inhibiting its activity. Indeed, recent clinical trials involving B-Raf selective inhibitors exhibited unprecedented response rates in metastatic melanoma patients. However, this therapeutic response is short-lived due to the emergence of several resistance mechanisms. Here we provide a review of our current knowledge on the regulation of this kinase under physiological circumstances and how this control is lost by mutations. We give an update on malignancies displaying high frequencies of BRAF mutations and discuss the mechanisms underlying the side effects and drug resistance phenomena associated with Raf inhibitors.


Articles with similar content:

Natural Products as Inhibitors of Epidermal Growth Factor Receptor
Forum on Immunopathological Diseases and Therapeutics, Vol.2, 2011, issue 4
Thomas Efferth
Tumor Protein D52 Overexpression and Gene Amplification in Cancers from a Mosaic of Microarrays
Critical Reviews™ in Oncogenesis, Vol.14, 2008, issue 1
Jayne R. Hardy, Jennifer A. Byrne, Judith Weidenhofer, Keerthi Thamotharampillai, Mona Shehata
Genetic and Epigenetic Control of RKIP Transcription
Critical Reviews™ in Oncogenesis, Vol.19, 2014, issue 6
Milad S. Bitar, Kevin Qin, Kam C. Yeung, Fahd Al-Mulla, Hanna Tegegne, Ila Datar, Robert J. Trumbly
Colorectal Cancer: A Multipathway Disease
Critical Reviews™ in Oncogenesis, Vol.12, 2006, issue 3-4
Jeremy R. Jass
Molecular Mechanisms Underlying the Role of MicroRNAs in Resistance to Epidermal Growth Factor Receptor-Targeted Agents and Novel Therapeutic Strategies for Treatment of Non-Small-Cell Lung Cancer
Critical Reviews™ in Oncogenesis, Vol.18, 2013, issue 4
Elena Galvani, Godefridus J. Peters, Mina Maftouh, Elisa Giovannetti, Amir Avan